Takeda reports Phase III data of vedolizumab for UC and Crohn's disease

Takeda Pharmaceuticals International has reported new data from GEMINI LTS (long-term safety), an ongoing, open-label extension Phase III trial of Entyvio (vedolizumab) to treat adults with moderately to severely active ulcerative colitis (UC) and Cr…
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news